Finance

Lists
Why is SPRB down 5.29%?
Dive Deeper
SPRB:NASDAQ
Spruce Biosciences, Inc
$46.73
-5.29%
(-2.61) 1D
Nov 10, 2:27:11 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPRB...
Open
$48.96
High
$48.96
Low
$44.74
Mkt. cap
134.30M
Avg. vol.
78.19K
Volume
42.95K
52-wk high
$127.90
52-wk low
$38.06
EPS
-$41.48
Beta
3.58
Shares outstanding
2.87M
No. of employees
22
Open
$48.96
High
$48.96
Low
$44.74
Mkt. cap
134.30M
Avg. vol.
78.19K
Volume
42.95K
52-wk high
$127.90
52-wk low
$38.06
EPS
-$41.48
Beta
3.58
Shares outstanding
2.87M
No. of employees
22
News stories
From web sources and news partners
About Spruce Biosciences, Inc
CEO-
Employees22
Founded2014
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websitesprucebio.com
Analyst ratings
Based on 6 analysts giving stock ratings to SPRB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for SPRB in the last 3 months.
Highest
Current $46.73
$230.00 (+392.19%)
Average
$155.50 (+232.76%)
Lowest
$104.00 (+122.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
$160.00
+242.4%
11/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$230.00
+392.2%
11/10/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$140.00
+199.6%
09/30/2026
Daniel Brims
Lake Street
Buy
Initiated
$149.00
+218.9%
09/17/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$150.00
+221%
08/26/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$230.00
+392.2%
08/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$104.00
+122.6%
08/17/2026
Catherine Novack
JonesTrading
Buy
Initiated
$135.00
+188.9%
06/08/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$120.00
+156.8%
05/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$150.00
+221%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
5.01M
-1.80M
7.58M
12.16M
Cost of revenue
5.01M
-1.80M
7.58M
12.16M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.22M
5.00M
4.41M
4.35M
Operating expense
3.22M
5.00M
4.41M
4.35M
Total operating expenses
8.23M
3.20M
11.99M
16.51M
Operating income
-8.23M
-3.20M
-11.99M
-16.51M
Other non operating income
-
-3.50M
-91.00K
615.00K
EBT including unusual items
-8.21M
-14.65M
-12.27M
-16.23M
EBT excluding unusual items
-8.21M
-6.75M
-12.27M
-16.23M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.21M
-14.65M
-12.27M
-16.23M
Net profit margin
-
-
-
-
Earnings per share
-14.58
-9.58
-8.94
-6.68
Interest and investment income
36.00K
-
486.00K
765.00K
Interest expense
-19.00K
-46.00K
-674.00K
-1.10M
Net interest expenses
17.00K
-46.00K
-188.00K
-332.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.23M
-3.20M
-11.74M
-15.88M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps